Eikon Therapeutics, Inc. 4

Column Group–affiliated insiders purchased 89,200 shares of Eikon Therapeutics, Inc. common stock on the open market for about $1.03 million.

Column Group–affiliated funds and principals reported an open-market purchase of 89,200 shares of Eikon Therapeutics, Inc. common stock on September 3, 2026 at a weighted average price of $11.5588 per share, for an aggregate consideration of approximately $1.03 million, with the actual trade prices ranging from $11.17 to $11.64. The newly purchased shares are reported as indirectly owned, with the securities directly held by Peter Svennilson and significant additional indirect holdings reported through The Column Group IV, LP, The Column Group IV-A, LP and The Column Group Opportunity III, LP, for post-transaction indirect ownership stakes of 4,312,139 shares, 148,840 shares, and 1,319,164 shares, respectively. The filing explains that various Column Group general partner entities, along with managing partners Peter Svennilson and Tim Kutzkey, may be deemed to share voting and investment power over these fund-held positions but each disclaims beneficial ownership beyond their pecuniary interest.

Filing Facts

CIK

1861123

Ticker

EIKN

Form

4

Source Type

fda

Accession

0001193125-26-385268

Alert Tier

8